Twitxy Saved

H3D

@H3D_UCT

H3D is the first and only centre of its kind on the African continent, an integrated drug discovery and development centre with TB, malaria and AMR platforms
Joined October 2020
159 Following 886 Followers 664 Posts

Latest posts 5

H3D @H3D_UCT
📣 New book chapter! "Multi-Target Antimalarials as a Strategy to Reduce Resistance Risk", written by Lauren B. Coulson and @Kelly_Chibale and appearing in "Polypharmacology: Strategies for Multi‐Target Drug Discovery" 💊 @UCTIDM @UCT_news onlinelibrary.wiley.com/doi/abs/10.100…
onlinelibrary.wiley.com Multi‐target Antimalarials as a Strategy to Reduce Resistance Risk Malaria remains a serious health concern, and it is critical that the drug development pipeline is constantly replenished with new candidate drugs to ...
H3D @H3D_UCT
Academic–industry #collaborations are a powerful catalyst for pharmaceutical innovation. Drawing on experiences at H3D, Winks et al. explore the benefits and challenges in the context of #drugdiscovery in this ACS Med. Chem. Lett. Viewpoint 💊 pubs.acs.org/doi/full/10.10…
pubs.acs.org Maximizing Potential: Academic–Industry Collaborations in Drug Discovery Abstract. Academic–industry collaborations are increasingly recognized as a catalyst for pharmaceutical innovation. While such partnerships are broadly val
H3D @H3D_UCT
Now out in #JMedChem! 💊 We report SARs for sapanisertib, identifying analogues with improved safety profiles and dual inhibitory activities against high-value Plasmodium targets PI4Kβ and PKG; a selected compound achieved an in vivo proof-of-concept 🐭 pubs.acs.org/doi/10.1021/ac…
pubs.acs.org Medicinal Chemistry Progression of Sapanisertib, the Anticancer and Dual Plasmodium Phosphatidyli... Abstract. We recently demonstrated that the anticancer human mTOR inhibitor sapanisertib displays antimalarial activity in a malaria mouse model of infecti